Halozyme Q1 revenue up 35% to $265M; raises FY25 guidance, announces $250M buyback

HALOZYME THERAPEUTICS, INC.

2025-Q1 EPS reported $0.93 revenue$264,861,000

Q1 revenue $264.9M (+35% YoY); GAAP EPS $0.93 (+55%); non-GAAP EPS $1.11 (+41%).
Raised 2025 guidance: revenue $1.2-1.28B (prev $1.15-1.225B), adj. EBITDA $790-840M, non-GAAP EPS $5.30-5.70.
Announced new $250M share repurchase; completed first $250M ASR in March 2025.
Filed patent infringement lawsuit against Merck over MDASE for subcutaneous Keytruda.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.